281
+3.69%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CellSource Co
Its shares trade on Tokyo Stock Exchange under the ticker 4880.T. It has been listed since 28 October 2019. In the fiscal year to 31 October 2025, it reported revenue of ¥3.71bn and net income of ¥10.7m. At that date it held total assets of ¥7.11bn and shareholders' equity of ¥6.02bn.
CellSource Co., Ltd. engages in regenerative medicine related business. The company is headquartered in Shibuya-Ku, Tokyo-To. The company went IPO on 2019-10-28. The firm operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 28 Oct 2019
- Employees
- 109
- Website
- cellsource.co.jp ↗
Leadership
Pay as last reported
- Dr. Masayuki YamakawaChairman of the Board, Representative Director, since 2015
- Mr. Takashi SawadaPresident, Chief Executive Officer, Representative Director, since 2022
- Ms. Kaoru HosodaExecutive Officer, Chief Operating Officer, Chief Director of Contract Processing Business
- Mr. Tomohiro IgaExecutive Officer
- Mr. Yuta HayashiExecutive Officer, Chief Strategy Officer, Chief Director of Business Strategy
- Mr. Masato TsumamotoChief Transformation Officer, Director, since 2015
- Mr. Takeshi AmemiyaDirector, since 2018
- Ms. Kumi FujisawaIndependent Director
- Mr. Tsuneyasu OzakiIndependent Director
- Ms. Yuka ShimadaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CellSource Co Ltd operates in the Life Sciences Tools & Services sector with 109 employees in Japan.
- The company provides regenerative medicine services including tissue processing and medical equipment sales.
- CellSource's Consumer business segment sells cosmetics and facial products to general consumers.
Weaknesses
- CellSource's Regenerative Medicine segment relies on contracted services for tissue processing from fat and blood.
- The company has only 109 employees, which may limit operational capacity.
- CellSource's Consumer business segment is limited to cosmetics and facial products sales.
Opportunities
- CellSource can expand its Regenerative Medicine segment in Japan's growing Health Care sector.
- The company may leverage its Life Sciences Tools & Services expertise for new market opportunities.
- CellSource's Consumer business segment could explore new product lines beyond cosmetics.
Threats
- CellSource faces regulatory challenges in Japan's Health Care sector for regenerative medicine.
- The company's Consumer business segment competes with established cosmetic brands in Japan.
- CellSource's limited employee count of 109 may hinder growth in competitive markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.